检索结果 - Claire E. Repellin
- Showing 1 - 6 results of 6
-
1
-
2
Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway 由 Alexis B. Cortot, Claire E. Repellin, Takeshi Shimamura, Marzia Capelletti, Kreshnik Zejnullahu, Dalia Ercan, James G. Christensen, Kwok‐Kin Wong, Nathanael S. Gray, Pasi A. Jänne
出版 2012Artigo -
3
Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases 由 Mahefatiana Andrianifahanana, Mark C. Wilkes, Shiv K. Gupta, Rod A. Rahimi, Claire E. Repellin, Maryanne Edens, Joshua Wittenberger, Xueqian Yin, Elizabeth Maidl, Jackson Becker, Edward B. Leof
出版 2013Artigo -
4
Concomitant inactivation of p53 and Chk2 in breast cancer 由 Alexandra Sullivan, Martin Yuille, Claire E. Repellin, Archana Reddy, Olivier Reelfs, Alexandra Bell, Barbara Dunne, Barry A. Gusterson, Peter Osin, Paul J. Farrell, Işık G. Yuluğ, Abigail Evans, Tayfun Özçelık, Milena Gasco, Tim Crook
出版 2002Artigo -
5
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors 由 Takayuki Kosaka, Junko Tanizaki, Raymond M. Paranal, Hideki Endoh, Christine Lydon, Marzia Capelletti, Claire E. Repellin, Jihyun Choi, Atsuko Ogino, Antonio Calles, Dalia Ercan, Amanda J. Redig, Magda Bahcall, Geoffrey R. Oxnard, Michael J. Eck, Pasi A. Jänne
出版 2017Artigo -
6
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors 由 Dalia Ercan, Chunxiao Xu, Masahiko Yanagita, Calixte S. Monast, Christine A. Pratilas, Joan Montero, Mohit Butaney, Takeshi Shimamura, Lynette M. Sholl, Elena Ivanova, Madhavi Tadi, Andrew M. Rogers, Claire E. Repellin, Marzia Capelletti, Ophélia Maertens, Eva M. Goetz, Anthony Letai, Levi A. Garraway, Matthew J. Lazzara, Neal Rosen, Nathanael S. Gray, Kwok‐Kin Wong, Pasi A. Jänne
出版 2012Artigo
相关主题
Biology
Cancer research
Biochemistry
Epidermal growth factor receptor
Receptor
Cancer
Cell biology
EGFR inhibitors
Gefitinib
Gene
Genetics
Pharmacology
Signal transduction
T790M
Breast cancer
Erlotinib
Growth factor
Mutation
Afatinib
Autocrine signalling
Carcinogenesis
Clathrin
Drug resistance
Endocytic cycle
Endocytosis
Endosome
Epidermal growth factor
ErbB
Exon
Germline mutation